

SPARC/Sec/SE/2024-25/001

April 04, 2024

National Stock Exchange of India Ltd.,

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051.

Scrip Symbol: SPARC

BSE Limited,

Market Operations Dept.

P. J. Towers, Dalal Street, Mumbai - 400 001.

Scrip Code: 532872

Dear Sir/Madam,

Sub: Initial disclosure to be made by entities identified as Large Corporates

Pursuant to SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021 ("SEBI Circular"), we hereby confirm that the Company is not a 'Large Corporate' as per the applicability criteria given under the SEBI Circular, for the FY 2024-25.

However, as per the directive issued by the National Stock Exchange of India Limited vide its email dated April 10, 2023, the initial disclosure as per the format prescribed under the SEBI Circular is as follows:

SI.	Particulars	Details
No.		
1	Name of the company	Sun Pharma Advanced Research
		Company Limited
2	CIN	L73100GJ2006PLC047837
3	Outstanding long-term borrowing of	NIL
	company as on March 31, 2024 (in Rs.	
	crore)	
4	Highest credit rating during the previous FY	Rating: ACUITE AA/Stable
	along with name of the CRA	Name of the CRA: Acuite Ratings &
		Research Limited
5	Name of stock exchange in which the fine	Not Applicable
	shall be paid, in case of shortfall in the	
	required borrowing under the framework	

We request you to kindly take the same on record.

Yours faithfully,

For Sun Pharma Advanced Research Company Limited

Chetan Rajpara Chief Financial Officer

Contact details: 022 6645 5999

Kajal Damania **Company Secretary**

Contact Details: 022 6645 5900